REGAN DEMSHAR: Open Payments
NPI 1972872059 · CLEVELAND, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$473 in 20 payments from 14 companies in 2025. Trend: 2023 $139 · 2024 $422 · 2025 $473
Food & beverage: $473
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 2 | $139 |
| Daiichi Sankyo Inc. | 4 | $83 |
| Genentech USA, Inc. | 2 | $39 |
| Rigel Pharmaceuticals, Inc. | 2 | $33 |
| Genmab U.S., Inc. | 1 | $27 |
| ADC THERAPEUTICS AMERICA, INC. | 1 | $24 |
| PFIZER INC. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Deciphera Pharmaceuticals Inc. | 1 | $17 |
| Incyte Corporation | 1 | $16 |
Products named: RYBREVANT, Enhertu, Tecentriq, DATROWAY, TAVALISSE, Tivdak, ZYNLONTA, PADCEV.
Industry payments across OH — which companies pay providers there.
